WallStreetZenWallStreetZen

NASDAQ: APLT
Applied Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for APLT

Based on 4 analysts offering 12 month price targets for Applied Therapeutics Inc.
Min Forecast
$7.00+59.45%
Avg Forecast
$11.00+150.57%
Max Forecast
$13.00+196.13%

Should I buy or sell APLT stock?

Based on 4 analysts offering ratings for Applied Therapeutics Inc.
Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their APLT stock forecasts and price targets.

APLT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-11
lockedlocked$00.00+00.00%2024-03-15Find Out Why
lockedlocked$00.00+00.00%2024-02-22
lockedlocked$00.00+00.00%2024-02-16Find Out Why

1 of 1

Forecast return on equity

Is APLT forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.19%

Forecast return on assets

Is APLT forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

APLT revenue forecast

What is APLT's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$17.2M
Avg 2 year Forecast
$72.6M
Avg 3 year Forecast
$82.6M

APLT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APLT$4.39$11.00+150.57%Strong Buy
VERV$6.01$30.00+399.17%Strong Buy
ALEC$5.25$17.75+238.10%Strong Buy
STTK$10.42$20.00+91.94%Buy
KALV$12.08$27.50+127.65%Buy

Applied Therapeutics Stock Forecast FAQ

Is Applied Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: APLT) stock is to Strong Buy APLT stock.

Out of 4 analysts, 2 (50%) are recommending APLT as a Strong Buy, 2 (50%) are recommending APLT as a Buy, 0 (0%) are recommending APLT as a Hold, 0 (0%) are recommending APLT as a Sell, and 0 (0%) are recommending APLT as a Strong Sell.

If you're new to stock investing, here's how to buy Applied Therapeutics stock.

What is APLT's revenue growth forecast for 2024-2026?

(NASDAQ: APLT) Applied Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.76%.

Applied Therapeutics's revenue in 2024 is -$477,000.On average, 1 Wall Street analysts forecast APLT's revenue for 2024 to be $1,965,398,970, with the lowest APLT revenue forecast at $1,965,398,970, and the highest APLT revenue forecast at $1,965,398,970. On average, 1 Wall Street analysts forecast APLT's revenue for 2025 to be $8,295,811,933, with the lowest APLT revenue forecast at $8,295,811,933, and the highest APLT revenue forecast at $8,295,811,933.

In 2026, APLT is forecast to generate $9,438,485,753 in revenue, with the lowest revenue forecast at $9,438,485,753 and the highest revenue forecast at $9,438,485,753.

What is APLT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: APLT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is APLT's Price Target?

According to 4 Wall Street analysts that have issued a 1 year APLT price target, the average APLT price target is $11.00, with the highest APLT stock price forecast at $13.00 and the lowest APLT stock price forecast at $7.00.

On average, Wall Street analysts predict that Applied Therapeutics's share price could reach $11.00 by Apr 11, 2025. The average Applied Therapeutics stock price prediction forecasts a potential upside of 150.57% from the current APLT share price of $4.39.

What is APLT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: APLT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.